Research

Hormonal

FDA-approved weight loss medications (liraglutide, lorcaserin, naltrexone-bupropion, orlistat, phentermine-topiramate) produce greater weight loss and diabetes risk reduction than placebo, but are associated with higher rates of adverse events and dropout.

If behavioral interventions alone are insufficient, FDA-approved weight loss medications can provide greater weight loss and diabetes risk reduction. However, be prepared for a higher likelihood of side effects and discontinuation. These medications should be used in conjunction with behavioral interventions.

ModerateQualifiesMEDIUM confidence
Participants randomized to weight loss medications had more weight loss, were more likely to lose 5% of their weight, and experienced a greater decrease in waist circumference than those on placebo... Weight loss medications were associated with more adverse events than placebo, which was associated with higher dropout rates for AEs in the medication than placebo groups.
Erin S. LeBlanc et al. · JAMA · 2018

Why this rating

Multiple RCTs but limited by high attrition, short follow-up in some trials, and variability in reporting.

Source

Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults

Erin S. LeBlanc et al. · JAMA · 2018

DOI 10.1001/jama.2018.7777

Meta-analysis · 124 studiesCited 450×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →